Structural analysis of a novel rabbit monoclonal antibody R53 targeting an epitope in HIV-1 gp120 C4 region critical for receptor and co-receptor binding

Emerging Microbes and Infections

Volumn 4, Issue 7, 2015, Pages

  Pan, Ruimin ^a   Chen, Yuxin ^b   Vaine, Michael ^b   Hu, Guangnan ^b   Wang, Shixia ^b   Lu, Shan ^b   Kong, Xiang Peng ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

C4; CD4; Env; HIV 1; Monoclonal antibody

Indexed keywords

ALANYLMETHIONYLTYROSYLALANYLPROLYLPROLYLISOLEUCINE; AMINO ACID DERIVATIVE; CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; EPITOPE; GLYCOPROTEIN GP 120; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY R53; RECEPTOR; UNCLASSIFIED DRUG; GP120 PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOGLOBULIN F(AB) FRAGMENT;

AMINO ACID SEQUENCE; ANTIGEN ANTIBODY REACTION; ANTIGEN BINDING; ARTICLE; CONSERVED SEQUENCE; CRYSTAL STRUCTURE; DRUG PROTEIN BINDING; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE SYSTEM; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN MOTIF; VIRUS STRAIN; ANIMAL; ANTIBODY COMBINING SITE; BINDING COMPETITION; CHEMISTRY; CRYSTALLIZATION; IMMUNOLOGY; ISOLATION AND PURIFICATION; METABOLISM; RABBIT; SHEEP;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD4; BINDING SITES, ANTIBODY; BINDING, COMPETITIVE; CRYSTALLIZATION; EPITOPES; HIV ENVELOPE PROTEIN GP120; IMMUNOGLOBULIN FAB FRAGMENTS; RABBITS; RECEPTORS, CCR5; RECEPTORS, CXCR4; SHEEP;

EID: 84989295890     PISSN: None     EISSN: 22221751     Source Type: Journal    
DOI: 10.1038/emi.2015.44     Document Type: Article

References (42)

1. Kwong PD, Doyle ML, Casper DJ et al. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 2002; 420: 678-682.
2. Pancera M, Zhou T, Druz A et al. Structure and immune recognition of trimeric prefusion HIV-1 Env. Nature 2014; 514: 455-461.
3. Jiang X, Burke V, TotrovMet al. Conserved structural elements in the V3 crown of HIV- 1 gp120. Nat Struct Mol Biol 2010; 17: 955-961.
4. Killikelly A, Zhang HT, Spurrier B et al. Thermodynamic signatures of the antigen binding site of mAb 447-52D targeting the third variable region of HIV-1 gp120. Biochemistry 2013; 52: 6249-6257.
5. Liao HX, Bonsignori M, Alam SM et al. Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity 2013; 38: 176-186.
6. Huang CC, Lam SN, Acharya P et al. Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4. Science 2007; 317: 1930-1934.
7. Julien JP, Cupo A, Sok D et al. Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science 2013; 342: 1477-1483.
8. Lyumkis D, Julien JP, de Val N et al. Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science 2013; 342: 1484-1490.
9. Modrow S, Hahn BH, Shaw GM, Gallo RC, Wong-Staal F, Wolf H. Computer-assisted analysis of envelope protein sequences of seven human immunodeficiency virus isolates: Prediction of antigenic epitopes in conserved and variable regions. J Virol 1987; 61: 570-578.
10. Ratner L, Fisher A, Jagodzinski LL et al. Complete nucleotide sequences of functional clones of the AIDS virus. AIDS Res Hum Retroviruses 1987; 3: 57-69.
11. Lasky LA, Nakamura G, Smith DH et al. Delineation of a region of the human immunodeficiency virus type 1 gp120 glycoprotein critical for interaction with the CD4 receptor. Cell 1987; 50: 975-985.
12. Rizzuto C, Sodroski J. Fine definition of a conserved CCR5-binding region on the human immunodeficiency virus type 1 glycoprotein 120. AIDS Res Hum Retroviruses 2000; 16: 741-749.
13. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998; 393: 648-659.
14. Rizzuto CD, Wyatt R, Hernandez-Ramos N et al. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. Science 1998; 280: 1949-1953.
15. Moore JP, ThaliM, Jameson BA et al. Immunochemical analysis of the gp120 surface glycoprotein of human immunodeficiency virus type 1: Probing the structure of the C4 and V4 domains and the interaction of the C4 domain with the V3 loop. J Virol 1993; 67: 4785-4796.
16. Wyatt R, Thali M, Tilley S et al. Relationship of the human immunodeficiency virus type 1 gp120 third variable loop to a component of the CD4 binding site in the fourth conserved region. J Virol 1992; 66: 6997-7004.
17. Hoffman NG, Seillier-Moiseiwitsch F, Ahn J, Walker JM, Swanstrom R. Variability in the human immunodeficiency virus type 1 gp120 Env protein linked to phenotypeassociated changes in the V3 loop. J Virol 2002; 76: 3852-3864.
18. Cease KB, Margalit H, Cornette JL et al. Helper T-cell antigenic site identification in the acquired immunodeficiency syndrome virus gp120 envelope protein and induction of immunity in mice to the native protein using a 16-residue synthetic peptide. Proc Natl Acad Sci USA 1987; 84: 4249-4253.
19. Berzofsky JA, Bensussan A, Cease KB et al. Antigenic peptides recognized by T lymphocytes from AIDS viral envelope-immune humans. Nature 1988; 334: 706-708.
20. Morrow WJ, Williams WM, Whalley AS et al. Synthetic peptides from a conserved region of gp120 induce broadly reactive anti-HIV responses. Immunology 1992; 75: 557-564.
21. Li H, Chien PC, Jr., Tuen M et al. Identification of an N-linked glycosylation in the C4 region of HIV-1 envelope gp120 that is critical for recognition of neighboring CD4 T cell epitopes. J Immunol 2008; 180: 4011-4021.
22. McKeating JA, Moore JP, Ferguson Met al. Monoclonal antibodies to the C4 region of human immunodeficiency virus type 1 gp120: Use in topological analysis of a CD4 binding site. AIDS Res Hum Retroviruses 1992; 8: 451-459.
23. Coussens PM, Tieber VL, Mehigh CS, Marcus M. Identification of a novel transcription factor, ACF, in cultured avian fibroblast cells that interacts with a Marek's disease virus late gene promoter. Virology 1991; 185: 80-89.
24. Sun NC, Ho DD, Sun CR et al. Generation and characterization of monoclonal antibodies to the putative CD4-binding domain of human immunodeficiency virus type 1 gp120. J Virol 1989; 63: 3579-3585.
25. Cordell J, Moore JP, Dean CJ, Klasse PJ, Weiss RA, McKeating JA. Rat monoclonal antibodies to nonoverlapping epitopes of human immunodeficiency virus type 1 gp120 block CD4 binding in vitro. Virology 1991; 185: 72-79.
26. Nakamura GR, Byrn R, Wilkes DM et al. Strain specificity and binding affinity requirements of neutralizing monoclonal antibodies to the C4 domain of gp120 from human immunodeficiency virus type 1. J Virol 1993; 67: 6179-6191.
27. Kwon YD, Finzi A, Wu X et al. Unliganded HIV-1 gp120 core structures assume the CD4-bound conformation with regulation by quaternary interactions and variable loops. Proc Natl Acad Sci U S A 2012; 109: 5663-5668.
28. Chen L, Kwon YD, Zhou T et al. Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120. Science 2009; 326: 1123-1127.
29. Zhou T, Xu L, Dey B et al. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 2007; 445: 732-737.
30. Chen Y, Vaine M, Wallace A et al. A novel rabbit monoclonal antibody platform to dissect the diverse repertoire of antibody epitopes for HIV-1 Env immunogen design. J Virol 2013; 87: 10232-10243.
31. Vaine M, Wang S, Crooks ET et al. Improved induction of antibodies against key neutralizing epitopes by human immunodeficiency virus type 1 gp120 DNA primeprotein boost vaccination compared to gp120 protein-only vaccination. J Virol 2008; 82: 7369-7378.
32. Burke V, Williams C, Sukumaran M et al. Structural basis of the cross-reactivity of genetically related human anti-HIV-1 mAbs: Implications for design of V3-based immunogens. Structure 2009; 17: 1538-1546.
33. Otwinowski Z, Minor W. Processing of X-ray diffraction data collected in oscillation mode. In: Carter CW, Sweet R, editors. Macromolecular Crystallography, Part A, Vol. 276. New York: Academic Press; 1997, pp 307-326.
34. Emsley P, Cowtan K. Coot: Model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 2004; 60: 2126-2132.
35. Adams PD, Grosse-Kunstleve RW, Hung LW et al. PHENIX: Building new software for automated crystallographic structure determination. Acta Crystallogr D Biol Crystallogr 2002; 58: 1948-1954.
36. Abagyan RA, Totrov M, Kuznetsov D. ICM - A new method for protein modeling and design: Applications to docking and structure prediction from the distorted native conformation. J Comput Chem 1994; 15: 488-506.
37. DeLano WL. The PyMOL User's Manual. Palo Alto, CA: DeLano Scientific; 2002.
38. Pan R, Sampson JM, Chen Y et al. Rabbit anti-HIV-1 monoclonal antibodies raised by immunization can mimic the antigen-binding modes of antibodies derived from HIV- 1-infected humans. J Virol 2013; 87: 10221-10231.
39. Kabat EA, Wu TT, Perry HM, Gottesman KS. Sequences of Proteins of Immunological Interest, 5th edn. Bethesda, MD: National Institutes of Health; 1991.
40. Xiang SH, Wang L, Abreu M et al. Epitope mapping and characterization of a novel CD4-induced human monoclonal antibody capable of neutralizing primary HIV-1 strains. Virology 2003; 315: 124-134.
41. Nakamura GR, Byrn R, Rosenthal K et al. Monoclonal antibodies to the extracellular domain ofHIV-1IIIB gp160 that neutralize infectivity, block binding to CD4, and react with diverse isolates. AIDS Res Hum Retroviruses 1992; 8: 1875-1885.
42. Kelker HC, Itri VR, Valentine FT. A strategy for eliciting antibodies against cryptic, conserved, conformationally dependent epitopes of HIV envelope glycoprotein. PLoS One 2010; 5: E8555.